Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation
Arthritis Rheumatol 2024. Epub ahead of print DOI: 10.1002/art.43037
Ma et al. assessed the efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) compared with dipeptidyl peptidase 4 inhibitors (DPP4i) in preventing cardiovascular and renal events in patients with both SLE and type 2 diabetes (T2D). SGLT2i use significantly reduced risks for acute kidney injury, chronic kidney disease, end-stage renal disease, and heart failure, though it increased genital infection risk.
The study used propensity-score-matched target trial emulation, comparing outcomes among SGLT2i and DPP4i initiators. Its aim was to evaluate if the cardiorenal benefits of SGLT2i extend to SLE patients with comorbid T2D who are at increased risk for such complications.